Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 ,inter alia, to consider and approve The Un-Audited Standalone and ....
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indoco Remedies has informed the stock exchanges that its Board of Directors will meet on Tuesday, 03 February 2026 to consider and approve the Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31 December 2025 (Q3 FY26). This is a routine regulatory intimation under SEBI Listing Regulations. Additionally, the trading window for dealing in the company's equity shares remains closed for designated persons and their immediate relatives until 05 February 2026, i.e., 48 hours after the results are declared.
This is a procedural filing with no immediate impact on shareholders or the stock price. Investors should watch for the actual Q3 FY26 results on 03 February 2026 for performance insights on revenue, margins, and profitability.